Although its potential efficacy has been proposed in some reports ,4, 12 most such speculations appear to be extended interpretations based on general moderation of NAFLD (especially NASH) observed in commonly used cholesterol‐lowering medications.13 More problematically, few studies have experimentally demonstrated an anti‐NAFLD effect of ezetimibe in terms of the hepatic NPC1L1 inhibition. Here, NPC1L1 is linked to metabolic dysfunction-associated steatohepatitis.